Navigation Links
Douglas Harrington, MD Speaks at American Academy of Physicians Assistants 2013 Conference in Washington, DC
Date:5/29/2013

IRVINE, Calif., May 29, 2013 /PRNewswire/ -- Aviir, Inc. attended the AAPA's Impact 2013 conference in Washington DC, as guests of GUARDaHEART, a non-profit foundation focused on Heart Disease awareness, at the Walter E. Washington Convention Center on May 28-29. Aviir's Chief Executive Officer Douglas Harrington , MD, presented on May 28, in the Product Theatre.

(Logo:  http://photos.prnewswire.com/prnh/20130319/LA79677LOGO)

"The presentation, 'Preventing Heart Disease: Identifying the Vulnerable Patient Before it is Too Late' discussed the clinical dilemma of at-risk patients being missed by current standard risk assessments, such as lipid panels and the Framingham ten year risk projection," said Dr. Harrington. "Fifty percent of heart attack patients have normal cholesterol levels, making early detection imperative to reducing risk before a cardiac event occurs and in halting disease progression early enough for the patient to improve their health."

During his presentation, Dr. Harrington also spoke about Aviir's MIRISK™ and MIRISK VP™ cardiac risk assessments. The MIRISK VP provides a net reclassification index improvement of 43 percent over Framingham, the current gold standard 10-year risk assessment, and was demonstrated in the MESA population. The test has applications across many medical specialties due to the prevalence of heart disease (750,000 new cases a year in the U.S. alone.).

Aviir has partnered with GUARDaHEART to promote Heart Disease awareness and prevention. Together, they have organized education events and fundraisers, and helped to make patient lifestyle modification a welcoming experience. GUARDaHEART's recommendations, activities, and events provide meaningful support and motivation to anyone interested in improving their heart health.

About Aviir
Aviir was founded in 2005 by cardiologists and scientists from the Stanford University School of Medicine to focus on discovery, development and commercialization of innovative diagnostic tests. The biotechnology company specializes in developing proprietary diagnostic tests to assist in identifying patients who are truly at high risk for the development of a cardiac event. Aviir's proprietary MIRISK and MIRISK VP assessments objectively identify, using a single blood draw, individuals who are at a high risk of experiencing a cardiac event over the next five years. Aviir's CLIA certified laboratory (Irvine, CA) complements these novel tests with a wide range of additional tests for heart health assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders – including pharmacogenomic and genetic tests. The company has adopted a unique clinical laboratory service model to provide physicians better diagnostic tools to help improve the cardiovascular health of their patients. The company is privately owned and funded by leading life science venture capital firms. Please visit www.aviir.com for more information.

About GUARDaHEART 
GUARDaHEART is a non-profit foundation dedicated to raising awareness of Heart Disease prevention by spreading the word to guard your heart and save your life. Cardiovascular disease is the leading cause of death in the United States. The good news is if individuals know their risk and take the necessary steps, most cardiovascular disease can be prevented and reversed if detected early. Although heart disease is typically diagnosed in adulthood, its roots are often found in childhood. Compelling research has shown that plaque buildup in the arterial walls begins very early in life and progresses throughout life. Intervention strategies and healthy lifestyle modification to reduce heart disease risk should begin early when reversal of the process is easier, not later in life when the disease is more developed. GUARDaHEART Foundation also provides assistance for individuals who are unable to pay for cardiac risk assessments. Please visit www.guardaheart.org for more information.

Company Contacts:
For media inquiries, please contact:
Tamara York 
Tamara York Public Relations, LLC 
212.967.8300

For Investor Relations, please contact:
Matt Clawson 
Life Capital Partners 
949.370.8500


'/>"/>
SOURCE Aviir, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Hagens Berman Sobol Shapiro LLP and Douglas & London P.C. Announce Proposed Class Action Settlement in Bayer Combination Aspirin Products Litigation
2. Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
3. Natalie Douglas, CEO von Idis, tritt Vorstand von Global Genes
4. RARE Project bei
5. Natalie Douglas, CEO of Idis, Joins Global Genes
6. RARE Project Board of Directors
7. Collegium Pharmaceutical Names Douglas Carlson to Vice President of Business Development
8. World Renowned Scientist, Dr. Rongxiang Xu Speaks Out About Nobel Assembly Statement Claiming They Have Not Heard Of Him
9. American Academy of Family Physicians Foundation Launches Cities for Life
10. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
11. Elsevier Selected as New Publisher of The American Journal of Geriatric Psychiatry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)...  Sequent Medical, Inc. announced today that it has ... safety and effectiveness of the WEB™ Aneurysm Embolization System ... Prof Laurent Spelle , MD, Head of Neuroradiology ... and Principal Investigator of the CLARYS study, ... and Germany.  Although patients with ruptured aneurysms have ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company ... Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would ... the UK, France , Italy ... to dilute the product only with dextrose solution.  ... 2015, the UK Court of Appeal held that Lilly,s patent ...
(Date:2/12/2016)... WILMINGTON, North Carolina , 12 februari ... Laboratories, Inc. (AAI/CML), een toonaangevende leverancier van ... farmaceutische en biotechnologische industrieën, kondigt vandaag een ... en mogelijkheden op haar locatie in ... in vraag heeft geleid tot meerdere recente ...
Breaking Medicine Technology:
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... ... Prater Eye Center becomes the first in the area to offer AngioPlex™ Optical ... signs of retinal disease, such as macular degeneration, diabetic retinopathy, and other vascular ...
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... Many individuals ... of protein for a multitude of reasons. IsoPasta by Isolator Fitness has delved ... it once more, but without the high-carb repercussions. IsoPasta has 30 grams of ...
(Date:2/13/2016)... ... February 13, 2016 , ... Christie Medical Holdings, ... gift of a VeinViewer® Vision vein finder for the nursing school ... an IV and draw blood, combining technology with traditional technique. , “VeinViewer is ...
(Date:2/12/2016)... CA (PRWEB) , ... February 12, 2016 , ... According ... hernia surgeries are beginning to account for a significant portion of hernia repairs throughout ... Towfigh of the Beverly Hills Hernia Center notes that this trend has not only ...
(Date:2/12/2016)... FL (PRWEB) , ... February 12, 2016 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – hosted over 250 members of South Florida’s philanthropic community at its 10th ...
Breaking Medicine News(10 mins):